chufangao/CTO huggingface dataset:
Clinical trial NCT02520011: Alvocidib Biomarker-driven Phase 2 AML Study
Official title: Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.
Enrollment: 104.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-14
Primary completion date: 2020-02-12
Completion date: 2020-02-12
Limitations and caveats: The protocol underwent a few major amendments to shorten time to complete and allow for an expeditious analysis and reporting of outcomes. The study was terminated early Jan 2020 due to marked decrease in enrollment and thus could not reach all of its efficacy endpoints. Only select analyses could be performed. Treatment efficacy was summarized by distributing the safety population into 6 groups based on whether the patients received ACM or CM regimen and their disease stages at study entry.
Plan to share individual participant data: NO
Clinical trial NCT03780634: HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Official title: Hepatic Artery Infusion Chemotherapy Plus Programmed Cell Death Protein-1 (PD-1) Antibody vs Hepatic Artery Infusion Chemotherapy Plus Sorafenib for Advanced Hepatocellular Carcinoma
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-01
Primary completion date: 2020-12-01
Completion date: 2021-12-01
Clinical trial NCT04469725: KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma
Official title: A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.
Enrollment: 95.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-02
Primary completion date: 2023-07-07
Completion date: 2023-07-07
Plan to share individual participant data: NO
Clinical trial NCT03823703: Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Sponsor: Corcept Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Suspended by sponsor, pending investigation of abnormal laboratory values in patients with NASH
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-11-04
Primary completion date: 2021-04-05
Completion date: 2021-04-05
Limitations and caveats: Due to observations related to safety, the study was terminated by the Sponsor prior to completion. The sample size at the time of study termination did not support formal tests to assess statistical differences between treatment groups, and therefore, no efficacy analyses specified in the protocol were performed. Descriptive statistics for efficacy endpoints are provided, but since no patient reached the Week 12 visit, and therefore, descriptive statistics at Week 12 are not presented.
Plan to share individual participant data: NO
Clinical trial NCT05047640: COVID-19 3rd Dose Vaccine in Transplant Patients
Official title: A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Difficulty in recruitment
Enrollment: 58.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-14
Primary completion date: 2022-10-25
Completion date: 2022-10-25
Plan to share individual participant data: NO
Clinical trial NCT03065712: Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET
Official title: Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET and Predictive Measure for Endocrine Therapy Response in Patients With Newly Diagnosed Metastatic Breast Cancer
Sponsor: University of Texas Southwestern Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Competing clinical trial
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-02-22
Primary completion date: 2020-02-22
Completion date: 2021-02-20
Plan to share individual participant data: NO
Clinical trial NCT04097314: Precision Medicine With Zibotentan in Microvascular Angina
Official title: A Randomised, Double-blind, Placebo-controlled, Cross-over Trial of Zibotentan in Microvascular Angina
Acronym: PRIZE
Sponsor: NHS Greater Glasgow and Clyde (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 225.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-18
Primary completion date: 2023-06-08
Completion date: 2023-06-08
Plan to share individual participant data: NO
Clinical trial NCT03127215: Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
Official title: A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Acronym: NCT-PMO-1603
Sponsor: National Center for Tumor Diseases, Heidelberg (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 102.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-25
Primary completion date: 2023-12-19
Completion date: 2023-12-19
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01952730: Pilot Study of GVAX in Colorectal Cancer Cells
Official title: A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Slow Accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2013-11-08
Primary completion date: 2018-09-30
Completion date: 2020-02-29
Clinical trial NCT02990845: Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
Official title: A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer
Acronym: PEER
Sponsor: National Taiwan University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The enrolment became difficult, as most of the premenopausal women decided to receive ovarian ablation for health insurance reimbursement for CDK4/6 inhibitor for the first-line treatment, making them ineligible for joining the study.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-15
Primary completion date: 2022-08-16
Completion date: 2022-08-16
Clinical trial NCT02991456: Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide
Official title: Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi®) Plus Ondansetron vs. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolomide
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-09
Primary completion date: 2022-05-09
Completion date: 2022-06-20
Clinical trial NCT00777491: Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
Official title: A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selective Bladder Preservation And Gemcitabine/Cisplatin Adjuvant Chemotherapy
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-12-31
Primary completion date: 2018-02-18
Completion date: 2022-05-20
Baseline population: Eligible patients
Limitations and caveats: Adverse event data was updated when outcome measure 5 was entered.
Clinical trial NCT05244954: Comparing Chemoprevention Approaches for School-based Malaria Control
Official title: Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission
Sponsor: University of Maryland, Baltimore (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 746.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-01
Primary completion date: 2022-08-26
Completion date: 2022-08-26
Plan to share individual participant data: YES
IPD sharing description: all individual participant data that underlie results in a publication
IPD time frame: After results publication
IPD access criteria: Public access with registration to allow tracking
Clinical trial NCT03493282: Effect of CT1812 Treatment on Brain Synaptic Density
Official title: A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease
Sponsor: Cognition Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-03-28
Primary completion date: 2020-10-16
Completion date: 2020-10-16
Plan to share individual participant data: NO
Clinical trial NCT01974206: A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 150.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-11-20
Primary completion date: 2016-05-13
Completion date: 2020-11-05
Baseline population: Randomized population: Age, Gender, Race, Ethnicity Randomized population: Use of ATG, Source of current Transplant, randomization strata
Plan to share individual participant data: YES
IPD sharing description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.
IPD time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
IPD access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Clinical trial NCT05057273: Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
Official title: A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
Sponsor: NImmune Biopharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Decision by Landos Biopharma (not related to safety or efficacy)
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-30
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Plan to share individual participant data: NO
Clinical trial NCT04945616: To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Official title: Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets Combined With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
Sponsor: Jiangsu HengRui Medicine Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-13
Primary completion date: 2021-10-19
Completion date: 2022-06-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05319756: Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
Official title: A Phase 4 Randomized Double-blind Double-dummy Placebo & Active-controlled Single-dose Six-way Crossover Study Evaluating Abuse Potential of NEURONTIN® Taken Orally With Oxycodone HCL in Healthy Non-drug Dependent Recreational Opioid Users
Sponsor: Viatris Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 54.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-04-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Baseline population: The randomized population included all participants who were randomized to a treatment sequence in the Treatment Phase.
Plan to share individual participant data: NO
Clinical trial NCT03068949: Comparison of Three Licensed Influenza Vaccines
Official title: A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine and Licensed Subvirion Influenza Vaccine Made in Eggs or Cell Culture in Healthy Adults.
Sponsor: University of Rochester (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 413.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-10-28
Primary completion date: 2020-06-30
Completion date: 2021-06-30
Plan to share individual participant data: YES
IPD sharing description: Data will be shared with the CEIRS (Centers of Excellence for Influenza Research and Surveillance) network
IPD time frame: 12 months
IPD access criteria: Broad Access
Clinical trial NCT03710941: Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenously Administered REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study was withdrawn due to an internal decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2020-08-27
Completion date: 2020-11-05
Clinical trial NCT03928821: Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
Official title: A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 27.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-07-17
Primary completion date: 2021-03-25
Completion date: 2021-03-25
Clinical trial NCT02594267: A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Official title: A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Sponsor: Acrotech Biopharma Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-10
Primary completion date: 2017-04-07
Completion date: 2020-10-08
Clinical trial NCT04127695: A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease
Official title: A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients With Parkinson's Disease
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Strategic considerations
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-03-03
Primary completion date: 2020-06-16
Completion date: 2020-06-16
Plan to share individual participant data: NO
Clinical trial NCT00979212: Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Official title: Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-02-28
Primary completion date: 2015-12-31
Completion date: 2022-05-20
Baseline population: All eligible patients receiving protocol treatment
Limitations and caveats: Following a recommendation on July 13, 2015 by the NRG Data Monitoring Committee accrual was halted early after accruing only 71 of 97 patients due to unexpectedly high rates of grade 5 toxicity on the panitumumab arm.
Clinical trial NCT04891497: Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
Official title: Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
Sponsor: Xuanwu Hospital, Beijing (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: There are no suitable patients
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-01
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation
Official title: Comparison of the Efficacy and Safety of Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Asthma Presenting at the Emergency Room for Moderate Exacerbation
Acronym: ASTHMAFAST
Sponsor: Centre Hospitalier Intercommunal Creteil (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Not enough recruitment in th trial
Enrollment: 102.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-23
Primary completion date: 2021-09-23
Completion date: 2023-06-23
Clinical trial NCT03440437: A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
Official title: A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Sponsor: invoX Pharma Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 80.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-04-16
Primary completion date: 2024-06-21
Completion date: 2024-06-21
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02498535: Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Official title: Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Sponsor: Novoteris, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated for the safety of cystic fibrosis clinical trial subjects due to Covid-19.
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-22
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT03060356: Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)
Official title: Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Halt in funding
Enrollment: 77.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-21
Primary completion date: 2020-03-27
Completion date: 2020-03-27
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04175392: Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
Official title: Effect of Probiotics in Non-Alcoholic Fatty Liver Disease and Steatohepatitis Measured by Transient Elastography (PRONE Study).
Acronym: PRONE
Sponsor: William Beaumont Hospitals (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: lack of enrollment
Enrollment: 14.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-12
Primary completion date: 2022-03-01
Completion date: 2022-03-01
Plan to share individual participant data: NO